No Data
No Data
Shareholders in Adaptive Biotechnologies (NASDAQ:ADPT) Have Lost 90%, as Stock Drops 7.4% This Past Week
Sector Update: Health Care Stocks Rise in Afternoon Trading
Adaptive Announces IVDR Certification for ClonoSEQ in European Union
Adaptive Biotechnologies to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
Scotiabank Maintains Adaptive Biotechnologies(ADPT.US) With Buy Rating, Maintains Target Price $10
Analysts Offer Insights on Healthcare Companies: CVRx (CVRX), Adaptive Biotechnologies (ADPT) and Rezolute (RZLT)
No Data
No Data